| 汪 敏,黄敏凤,池 俊,等.人表皮生长因子受体2低表达乳腺癌病理检测及其异质性研究进展[J].肿瘤学杂志,2023,29(5):420-424. |
| 人表皮生长因子受体2低表达乳腺癌病理检测及其异质性研究进展 |
| Research Progress on Clinical and Pathological Characteristics of HER2-Low Breast Cancer |
| 投稿时间：2023-02-16 |
| DOI：10.11735/j.issn.1671-170X.2023.05.B012 |
|
 |
| 中文关键词: 人表皮生长因子受体2 乳腺癌 病理检测 临床特征 |
| 英文关键词:human epidermal growth factor receptor 2 breast cancer pathological examination clinical features |
| 基金项目:国家自然科学基金（82260604） |
|
| 摘要点击次数: 441 |
| 全文下载次数: 201 |
| 中文摘要: |
| 摘 要：人表皮生长因子受体2（human epidermal growth factor receptor 2，HER2）是乳腺癌的生物标志物之一。近年研究表明以曲妥珠单抗德鲁特康(T-DXd)、曲妥珠单抗多卡木嗪(SYD985）为代表的新型抗体药物偶联物可能使HER2低表达乳腺癌患者受益。按照目前的评分系统，HER2低表达乳腺癌患者占所有乳腺癌总数一半以上，从靶向治疗中获益的患者或可达到60%~70%。然而，HER2低表达乳腺癌是否具有独特生物学特异性的临床亚型尚有争议。 |
| 英文摘要: |
| Abstract： Human epidermal growth factor receptor 2(HER2) is one of the biomarkers of breast cancer. Studies have shown that the antibody-drug conjugates(ADC) trastuzumab drutecan(T-DXd) and trastuzumab doxarxyzine(SYD985) may benefit patients with HER2-low breast cancer. HER2-low expression breast cancer account for more than half of all breast cancer， and the patients who may benefit from targeted therapy would reach 60%~70%. However， whether HER2-low breast cancer is a clinical subtype with unique biological specificity is still controversial at present. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|